Kalaris Therapeutics, Inc.

Developing next-gen, long-acting anti-VEGF therapies for prevalent retinal diseases.

KLRS | US

Overview

Corporate Details

ISIN(s):: US0198181036
LEI:
Country:: United States of America
Address:: 628 MIDDLEFIELD ROAD, 94301 PALO ALTO
Website:: https://kalaristx.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Kalaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing treatments for prevalent retinal diseases. The company's lead product candidate is TH103, a fully humanized, recombinant fusion protein designed as a next-generation anti-VEGF agent for intravitreal delivery. Co-developed by Dr. Napoleone Ferrara, known for his work on Avastin and Lucentis, TH103 acts as a soluble decoy receptor. A key feature is its high affinity for heparan sulfate proteoglycans (HSPG), which may act as a molecular anchor to extend its intraocular retention. This mechanism aims to reduce the frequency of injections for patients with neovascular retinal diseases, such as age-related macular degeneration.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Kalaris Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Kalaris Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Kalaris Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
Immatics N.V. Develops T-cell redirecting immunotherapies (ACT & TCR Bispecifics) for solid tumor cancers.	United States of America	IMTX
Immix Biopharma, Inc. Developing safer cell therapies for AL Amyloidosis and hematologic malignancies.	United States of America	IMMX
IMMUCELL CORP /DE/ Develops biotech health products for disease prevention in dairy and beef cattle.	United States of America	ICCC
Immuneering Corp Clinical-stage oncology firm using bioinformatics to develop oral MEK inhibitors for solid tumors.	United States of America	IMRX
ImmuneOncia Therapeutics, Inc. A biopharma firm developing immune checkpoint inhibitors for cancer immunotherapy.	South Korea	424870
ImmunityBio, Inc. Develops immunotherapies activating the immune system to fight cancer and infectious diseases.	United States of America	IBRX
Immuno-Biological Laboratories Co., Ltd. Develops and supplies immunological reagents and diagnostics for research and drug discovery.	Japan	4570
Immunocore Holdings plc Pioneering TCR bispecific immunotherapies for cancer, infectious, and autoimmune diseases.	United States of America	IMCR
Immunome Inc. Develops targeted oncology therapies, like ADCs, for cancers with high unmet needs.	United States of America	IMNM
Immunovant, Inc. Developing novel, FcRn-targeted therapies for people with autoimmune diseases.	United States of America	IMVT